WO/2016/075513 SUCTIONING DEVICE FOR LARGE ARTIFICIAL WATER BODIES||WO||19.05.2016|
||PCT/IB2014/065981||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN TORRES, Fernando Benjamin|
The present invention relates to a flexible suctioning device for suctioning floes from the bottom of large artificial water bodies with surfaces larger than 10,000 m and with bottoms covered with plastic liners that do not have centralized filtration systems, and that is able to clean a bottom surface of large artificial water bodies at a surface cleaning rate of 325,000 ft 2 per 24 hours (30,000 m2 per 24 hours) or more, where the bottom surface of the large artificial water bodies can be irregular and sloped, and where the suctioning device is reversible and is supported by a plurality of brushes, comprising first brushes, disposed to provide appropriate support to the suction device and minimize the dispersion and re-suspension of settled floes. The suctioning device is designed in order to concentrate the suction power in a series of suction points, where the suctioning device is connected to an external filtration system that may not be attached to the suctioning device.
WO/2015/107495 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2||WO||23.07.2015|
||PCT/IB2015/050345||NOVARTIS AG||CHEN, Christine Hiu-tung|
The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
WO/2015/099029 INJECTABLE AGENT AND DEPOT FORMATION METHOD||WO||02.07.2015|
||PCT/JP2014/084289||SANTEN PHARMACEUTICAL CO., LTD.||OKI, Kenji|
The purpose of the present invention is to provide a novel injectable agent having an excellent medicinal agent sustained release property.
The injectable agent according to the present invention comprises a medicinal agent, trehalose and gellan gum. It is preferred that the contents of the medicinal agent, trehalose and gellan gum are 0.0001 to 50.00% (w/v), 0.1 to 50.0% (w/v) and 0.01 to 3.00% (w/v), respectively, relative to the total volume of the injectable agent. It is also preferred that the injectable agent can form a depot upon the contact with a phosphate buffer solution or a body fluid (tear fluid, vitreous fluid, etc.).
WO/2015/097713 NOVEL HETEROCYCLIC COMPOUNDS||WO||02.07.2015|
||PCT/IN2014/000704||CADILA HEALTHCARE LIMITED||DESAI, Ranjit, C.|
The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
WO/2015/091805 QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS||WO||25.06.2015|
||PCT/EP2014/078475||H. LUNDBECK A/S||KEHLER, Jan|
The present invention provides Quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
WO/2015/092638 N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDONE POLYMORPHIC FORMS||WO||25.06.2015|
||PCT/IB2014/066849||JSC OLAINFARM||LIEPINS, Vilnis|
The invention is related to N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidone crystalline polymorphic forms and their production methods, as well as to the use of said polymorphic forms for pharmaceutical compositions manufacturing.
WO/2015/087156 SYSTEM AND METHOD FOR MAINTAINING WATER QUALITY IN LARGE WATER BODIES||WO||18.06.2015|
||PCT/IB2014/002891||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN TORRES, Fernando Benjamin|
Energy saving installation and method for treating large water bodies wherein the method comprises: (a) applying an effective amount of a flocculent to water in the water body to maintain turbidity of the water below 2 NTU, wherein the flocculent flocculates suspended solids in the water into particles that settle to the bottom of the water body. (b) operating a mobile suctioning device to maintain an increase in the black component of the bottom's colour below 30% based on the CMYK scale, wherein the mobile suction device suctions a portion of water from the bottom of the water body containing settled particles, and wherein the device is capable of cleaning at a surface cleaning rate of 10,000m2/24 hours; (c) filtering the water suctioned by the mobile suction device and returning the filtered water to the water body, wherein the water suctioned by the mobile suction device does not exceed 10% of the total water volume of the water body in a 24 hour interval; and (d) operating a degreasing system to maintain a surface water layer having less than about 20 mg/L of floating greases, wherein greases from a surface water flow into the degreasing system are removed by a separation unit comprising a degreaser and the treated water is returned to the water body.
WO/2015/086491 DRUG DELIVERY SYSTEM.||WO||18.06.2015|
||PCT/EP2014/076823||MERCK SHARP & DOHME B.V.||VERHOEVEN, Willy J. H.|
Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii)a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.
WO/2015/083028 PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES||WO||11.06.2015|
||PCT/IB2014/066202||PFIZER INC.||BROWN, Matthew Frank|
The present invention provides pharmaceutically active pyrrolo[2,3- d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
WO/2015/075598 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS||WO||28.05.2015|
||PCT/IB2014/065935||PFIZER INC.||BEHENNA, Douglas Carl|
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.